Moberg

Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)

Retrieved on: 
Friday, November 6, 2020
Mucositis, Moberg

Moberg Pharma estimates the capital requirement to take BupiZenge through phase 3 at SEK 60 million.

Key Points: 
  • Moberg Pharma estimates the capital requirement to take BupiZenge through phase 3 at SEK 60 million.
  • Moberg Pharma is therefore evaluating the opportunity to distribute OncoZenge according to Lex Asea and list its shares on Nasdaq First North Growth Market.
  • Moberg Pharma has since 2014 been developing BupiZenge for treatment of pain in connection with Oral Mucositis ("OM").
  • The proposal to distribute shares in OncoZenge will require the approval of an extraordinary general meeting of Moberg Pharma, which Moberg Pharma has convened today.

Moberg Pharma intends to submit a registration application in Europe in 2021

Retrieved on: 
Wednesday, October 14, 2020
Moberg

In June, Moberg Pharma presented topline results from the second of two clinical Phase 3 studies for MOB-015.

Key Points: 
  • In June, Moberg Pharma presented topline results from the second of two clinical Phase 3 studies for MOB-015.
  • Moberg Pharma will now finalize the documentation for the registration application which the company expects to submit during the second half of 2021.
  • Moberg Pharma has secured commercialization partners for MOB-015 in Europe, Japan, Canada and the Republic of Korea.
  • This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

Moberg Pharma intends to submit a registration application in Europe in 2021

Retrieved on: 
Wednesday, October 14, 2020
Moberg

In June, Moberg Pharma presented topline results from the second of two clinical Phase 3 studies for MOB-015.

Key Points: 
  • In June, Moberg Pharma presented topline results from the second of two clinical Phase 3 studies for MOB-015.
  • Moberg Pharma will now finalize the documentation for the registration application which the company expects to submit during the second half of 2021.
  • Moberg Pharma has secured commercialization partners for MOB-015 in Europe, Japan, Canada and the Republic of Korea.
  • This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

Moberg Pharma's Interim report for July 2019 - June 2020 to be published on August 11 - Invitation to teleconference

Retrieved on: 
Tuesday, August 4, 2020
Nasdaq Nordic, Moberg

STOCKHOLM, Aug. 4, 2020 /PRNewswire/ -- On August 11th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - June 2020.

Key Points: 
  • STOCKHOLM, Aug. 4, 2020 /PRNewswire/ -- On August 11th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - June 2020.
  • Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
  • The teleconference will be hosted by Moberg Pharmas's CEO Anna Ljung and VP Finance Mark Beveridge.
  • To participate in the conference, please dial in on any number below before the start of the call:

Appointment of Chief Medical Officer at Moberg Pharma

Retrieved on: 
Thursday, July 30, 2020
Moberg

STOCKHOLM, July 30, 2020 /PRNewswire/ --Moberg Pharma AB (OMX: MOB) announces the appointment of Dr Cindy Wong as Chief Medical Officer of Moberg Pharma.

Key Points: 
  • STOCKHOLM, July 30, 2020 /PRNewswire/ --Moberg Pharma AB (OMX: MOB) announces the appointment of Dr Cindy Wong as Chief Medical Officer of Moberg Pharma.
  • Dr Wong will during the fall be joining the management team at Moberg Pharma coming from a previous position as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH.
  • Moberg Pharma is pleased to announce the appointment of Dr Cindy Wong as Chief Medical Officer.
  • This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

New Number of Shares and Votes in Moberg Pharma AB (publ)

Retrieved on: 
Friday, May 29, 2020
Stock market, Corporate finance, Equity securities, Financial economics, Finance, Nasdaq Nordic, Moberg, Share

STOCKHOLM, May 29, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 19,223,510.

Key Points: 
  • STOCKHOLM, May 29, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 19,223,510.
  • As per 29 May 2020, the total number of shares in Moberg Pharma AB (publ) amounts to 19,223,510.
  • All shares are common shares.
  • The increase in the number of shares and votes results from an issue of 370,000 class C shares.

Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020

Retrieved on: 
Tuesday, May 12, 2020
Health, Moberg, Clinical trial, Outcome, Endpoint, Pharmacology

The agreement enables Moberg Pharma to conduct an additional clinical study, depending on the outcome of the EU study.

Key Points: 
  • The agreement enables Moberg Pharma to conduct an additional clinical study, depending on the outcome of the EU study.
  • In December 2019, Moberg Pharma reported that the primary endpoint for MOB-015 had been met in the North American phase 3 study.
  • CONFERENCE CALL - MAY 12, 2020 AT 3:00 P.M CET
    CEO Anna Ljung will present the report at a telephone conference on May 12, 2020, at 3:00 p.m CET.
  • The information was submitted for publication, through the agency of the contact persons set out below, at 8.00 a.m. CET on May 12, 2020.

Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference

Retrieved on: 
Tuesday, May 5, 2020
Nasdaq Nordic, Moberg, Companies

STOCKHOLM, May 5, 2020 /PRNewswire/ -- On May 12th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - March 2020.

Key Points: 
  • STOCKHOLM, May 5, 2020 /PRNewswire/ -- On May 12th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - March 2020.
  • Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
  • The teleconference will be hosted by Moberg Pharmas's CEO Anna Ljung and VP Finance Mark Beveridge.
  • To participate in the conference, please dial in on any number below before the start of the call:

Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015

Retrieved on: 
Monday, March 23, 2020
Moberg

The financing is provided by N&G, a Swiss specialty investor focusing on financing solutions for public biotech and cleantech growth companies.

Key Points: 
  • The financing is provided by N&G, a Swiss specialty investor focusing on financing solutions for public biotech and cleantech growth companies.
  • "The agreement provides Moberg Pharma access to flexible financing at a reasonable cost under current market conditions.
  • As part of the agreement, Nice & Green will introduce Moberg Pharma to its wide network of biotech investors in Switzerland, Germany and France," says Mark Beveridge, VP Finance at Moberg Pharma.
  • To facilitate the financing agreement, the company's largest shareholder, stersjstiftelsen, has entered into an agreement to lend N&G shares in Moberg Pharma.

Bulletin from Moberg Pharma's AGM 2019

Retrieved on: 
Wednesday, May 15, 2019
Moberg, Pharma

STOCKHOLM, May 15, 2019 /PRNewswire/ -- Moberg Pharma AB's ("Company") Annual General Meeting took place on Wednesday, May 15th, 2019 in the Companys premises in Bromma, Sweden.

Key Points: 
  • STOCKHOLM, May 15, 2019 /PRNewswire/ -- Moberg Pharma AB's ("Company") Annual General Meeting took place on Wednesday, May 15th, 2019 in the Companys premises in Bromma, Sweden.
  • The Meeting resolved to approve the Board of Director's proposal for principles of remuneration to senior executives in Moberg Pharma.
  • Immediately following the General Meeting and in accordance with the proposal dated on April 8th, 2019 ( http://www.mobergpharma.com/press-releases/2019-04-08/proposed-managemen... ), the Board of Directors resolved to elect Anna Ljung as the new Chief Executive Officer of Moberg Pharma AB.
  • Moberg Pharma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act.